Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Liabilities and Shareholders Equity (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 20.85% to $1.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.6 billion, a 7.83% increase, with the full-year FY2025 number at $1.3 billion, up 20.85% from a year prior.
  • Liabilities and Shareholders Equity was $1.3 billion for Q4 2025 at Madrigal Pharmaceuticals, down from $1.4 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q3 2025 to a low of $158.6 million in Q3 2022.
  • A 5-year average of $631.1 million and a median of $347.5 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: plummeted 47.93% in 2022, then skyrocketed 351.02% in 2024.
  • Madrigal Pharmaceuticals' Liabilities and Shareholders Equity stood at $273.3 million in 2021, then soared by 32.65% to $362.6 million in 2022, then soared by 76.67% to $640.5 million in 2023, then soared by 62.71% to $1.0 billion in 2024, then grew by 20.85% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Liabilities and Shareholders Equity are $1.3 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.0 billion (Q2 2025).